Discharge locations after hospitalizations involving opioid use disorder among medicare beneficiaries
Tóm tắt
Hospitalizations involving opioid use disorder (OUD) have been increasing among Medicare beneficiaries of all ages. With rising OUD-related acute care use comes the need to understand where post-acute care is provided and the capacities for OUD treatment in those settings. Our objective was to describe hospitalized Medicare beneficiaries with OUD, their post-acute care locations, and all-cause mortality and readmissions stratified by post-acute care location. We conducted a retrospective cohort study of acute hospitalizations using 2016–2018 Medicare Provider Analysis and Review (MedPAR) files linked to Medicare enrollment data and the Residential History File (RHF) for 100% of Medicare fee-for-service beneficiaries. The RHF which provides a person-level chronological history of health service utilization and locations of care was used to identify hospital discharge locations. We used ICD-10 codes for opioid dependence or “abuse” to identify OUD diagnoses from the MedPAR file. We conducted logistic regression to identify factors associated with discharge to an institutional setting versus home adjusting for demographics, comorbidities, and hospital stay characteristics. Our analysis included 459,763 hospitalized patients with OUD. Of these, patients aged < 65 years and those dually enrolled in Medicaid comprised the majority (59.1%). OUD and opioid overdose were primary diagnoses in 14.3% and 6.2% of analyzed hospitalizations, respectively. We found that 70.3% of hospitalized patients with OUD were discharged home, 15.8% to a skilled nursing facility (SNF), 9.6% to a non-SNF institutional facility, 2.5% home with home health services, and 1.8% died in-hospital. Within 30 days of hospital discharge, rates of readmissions and mortality were 29.7% and 3.9%; respectively, with wide variation across post-acute locations. Factors associated with greater odds of discharge to institutional settings were older age, female sex, non-Hispanic White race and ethnicity, dual enrollment, longer hospital stay, more comorbidities, intensive care use, surgery, and primary diagnoses including opioid or other drug overdoses, fractures, and septicemia. More than one-quarter (25.8%) of hospitalized Medicare beneficiaries with OUD received post-acute care in a setting other than home. High rates and wide variation in all-cause readmissions and mortality within 30 days post-discharge emphasize the need for improved post-acute care for people with OUD.
Tài liệu tham khảo
Lembke A, Chen JH. Use of opioid agonist therapy for medicare patients in 2013. JAMA Psychiat. 2016;73(9):990–2.
Han BH, Sherman SE, Palamar JJ. Prescription opioid misuse among middle-aged and older adults in the United States, 2015–2016. Prev Med. 2019;121:94–8.
Orhurhu V, Olusunmade M, Urits I, et al. Trends of opioid use disorder among hospitalized patients with chronic pain. Pain Pract. 2019;19(6):656–63.
Rubin R. Opioid-related problems increasing among older adults. JAMA. 2018;320(20):2067.
Zullo AR, Moyo P, Jutkowitz E, Zhang W, Thomas KS. Opioid use disorder among hospitalized older adults: prevalence, characteristics, and discharge status. J Am Med Dir Assoc. 2020;21(4):557–9.
Weiss AJ, Heslin KC, Barrett ML, Izar R, Bierman AS. Opioid-Related Inpatient Stays and Emergency Department Visits Among Patients Aged 65 Years and Older, 2010 and 2015. Healthcare Cost and Utilization Project. Statistical Brief #244. 2018.
Shoff C, Yang TC, Shaw BA. Trends in Opioid Use Disorder Among Older Adults: Analyzing Medicare Data, 2013–2018. Am J Prev Med. 2021;60(6):850–5.
Statistical Brief #256. Healthcare Cost and Utilization Project (HCUP). April 2020. Agency for Healthcare Research and Quality, https://www.hcup-us.ahrq.gov/reports/statbriefs/sb256-Opioids-Endocarditis-Inpatient-Stays-2016.jsp. Accessed 20 Jan 2022.
Zullo AR, Danko KJ, Moyo P, et al. Prevention, diagnosis, and management of opioids, opioid misuse, and opioid use disorder in older adults. Rockville: Agency for Healthcare Research and Quality; 2020.
West NA, Dart RC. Prescription opioid exposures and adverse outcomes among older adults. Pharmacoepidemiol Drug Saf. 2016;25(5):539–44.
Carew AM, Comiskey C. Treatment for opioid use and outcomes in older adults: a systematic literature review. Drug Alcohol Depend. 2018;182:48–57.
Lauer EA, Henly M, Brucker DL. Prescription opioid behaviors among adults with and without disabilities - United States, 2015–2016. Disabil Health J. 2019;12(3):519–22.
Manchikanti L, Pampati V, Falco FJ, Hirsch JA. An updated assessment of utilization of interventional pain management techniques in the Medicare population: 2000–2013. Pain Physician. 2015;18(2):E115-127.
Patel KV, Guralnik JM, Phelan EA, et al. Symptom burden among community-dwelling older adults in the United States. J Am Geriatr Soc. 2019;67(2):223–31.
Pasquale MK, Joshi AV, Dufour R, et al. Cost drivers of prescription opioid abuse in commercial and Medicare populations. Pain Pract. 2014;14(3):E116-125.
Simoni-Wastila L, Yang HK. Psychoactive drug abuse in older adults. Am J Geriatr Pharmacother. 2006;4(4):380–94.
Khan NF, Bykov K, Glynn RJ, Barnett ML, Gagne JJ. Coprescription of opioids with other medications and risk of opioid overdose. Clin Pharmacol Ther. 2021;110(4):1011–7.
Salive ME. Multimorbidity in older adults. Epidemiol Rev. 2013;35:75–83.
Moyo P. Opioid use disorder and its treatment among older adults: an invited commentary. Am J Geriatr Psychiatry. 2019;27(4):346–8.
Fox MH, Reichard A. Disability, health, and multiple chronic conditions among people eligible for both Medicare and Medicaid, 2005–2010. Prev Chronic Dis. 2013;10:E157.
Jenq GY, Tinetti ME. Post-acute care: who belongs where? JAMA Intern Med. 2015;175(2):296–7.
Burke RE, Cumbler E, Coleman EA, Levy C. Post-acute care reform: Implications and opportunities for hospitalists. J Hosp Med. 2017;12(1):46–51.
Han BH. Aging, multimorbidity, and substance use disorders: the growing case for integrating the principles of geriatric care and harm reduction. Int J Drug Policy. 2018;58:135–6.
Intrator O, Hiris J, Berg K, Miller SC, Mor V. The residential history file: studying nursing home residents’ long-term care histories(*). Health Serv Res. 2011;46(1 Pt 1):120–37.
Cole ES, DiDomenico E, Cochran G, et al. The role of primary care in improving access to medication-assisted treatment for rural medicaid enrollees with opioid use disorder. J Gen Intern Med. 2019;34(6):936–43.
Kimmel SD, Rosenmoss S, Bearnot B, Larochelle M, Walley AY. Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts. J Addict Med. 2021;15(1):20–6.
Kimmel SD, Rosenmoss S, Bearnot B, et al. Northeast postacute medical facilities disproportionately reject referrals for patients with opioid use disorder. Health Aff (Millwood). 2022;41(3):434–44.
Pytell JD, Sharfstein JM, Olsen Y. Facilitating methadone use in hospitals and skilled nursing facilities. JAMA Intern Med. 2019. https://doi.org/10.1001/jamainternmed.2019.5731.
Pytell JD, Sharfstein JM, Olsen Y. Additional barriers to methadone use in hospitals and skilled nursing facilities-reply. JAMA Intern Med. 2020;180(4):615.
Dineen KK. Disability discrimination against people with substance use disorders by postacute care nursing facilities: it is time to stop tolerating civil rights violations. J Addict Med. 2021;15(1):18–9.
Sun JW, Rogers JR, Her Q, et al. Adaptation and validation of the combined comorbidity score for ICD-10-CM. Med Care. 2017;55(12):1046–51.
Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–59.
Moreno JL, Wakeman SE, Duprey MS, Roberts RJ, Jacobson JS, Devlin JW. Predictors for 30-day and 90-day hospital readmission among patients with opioid use disorder. J Addict Med. 2019;13(4):306–13.
Weiss AJ, Jiang HJ. Overview of clinical conditions with frequent and costly hospital readmissions by payer, 2018. HCUP statistical brief #278. Rockville: MD Agency for Healthcare Research and Quality; 2021.
Larney S, Bohnert AS, Ganoczy D, et al. Mortality among older adults with opioid use disorders in the veteran’s health administration, 2000–2011. Drug Alcohol Depend. 2015;147:32–7.
National Academies of Sciences Engineering and Medicine. Future directions for the demography of aging: proceedings of a workshop. Washington: The National Academies Press; 2018. https://doi.org/10.17226/25064.
Colby SL, Ortman JM. The baby boom cohort in the United States: 2012 to 2060: population estimates and projections. U.S. Census Bureau; 2014.
Wu LT, Blazer DG. Illicit and nonmedical drug use among older adults: a review. J Aging Health. 2011;23(3):481–504.
Patterson TL, Jeste DV. The potential impact of the baby-boom generation on substance abuse among elderly persons. Psychiatr Serv. 1999;50(9):1184–8.
O’Malley PA. Baby boomers and substance abuse: the curse of youth again in old age: implications for the clinical nurse specialist. Clin Nurse Spec. 2012;26(6):305–7.
Mospan GA, Chaplin M. Initiation of buprenorphine for opioid use disorder in the hospital setting: Practice models, challenges, and legal considerations. Am J Health Syst Pharm. 2021. https://doi.org/10.1093/ajhp/zxab373.
Barbosa-Leiker C, Campbell ANC, McHugh RK, Guille C, Greenfield SF. Opioid Use Disorder in Women and the Implications for Treatment. Psychiatr Res Clin Pract. 2021;3(1):3–11.
Office of Inspector General. U.S. Department of Health and Human Services. Many medicare beneficiaries are not receiving medication to treat their opioid use disorder. Data brief: OEI-02–20–00390. December 2021. OEI-02–20–00390.
Harris SJ, Abraham AJ, Andrews CM, Yarbrough CR. Gaps in access to opioid use disorder treatment for medicare beneficiaries. Health Aff (Millwood). 2020;39(2):233–7.
Parish WJ, Mark TL, Weber EM, Steinberg DG. Substance use disorders among medicare beneficiaries: prevalence, mental and physical comorbidities, and treatment barriers. Am J Prev Med. 2022;63(2):225–32.
Wakeman SE, Rich JD. Barriers to post-acute care for patients on opioid agonist therapy; an example of systematic stigmatization of addiction. J Gen Intern Med. 2017;32(1):17–9.
Gifford D, Harmon H, Truscott P. Additional barriers to methadone use in hospitals and skilled nursing facilities. JAMA Intern Med. 2020;180(4):615.
Cotton BP, Bryson WC, Bruce ML. Methadone maintenance treatment for older adults: cost and logistical considerations. Psychiatr Serv. 2018;69(3):338–40.
Han BH, Moore AA, Levander XA. To care for older adults with substance use disorder, create age-friendly health systems. Health Aff Forefr. 2022. https://doi.org/10.1377/forefront.20220505.917481.
Jutkowitz E, Halladay C, McGeary J, O’Toole T, Rudolph JL. Homeless veterans in nursing homes: care for complex medical, substance use, and social needs. J Am Geriatr Soc. 2019;67(8):1707–12.
Laws MB, Beeman A, Haigh S, Wilson IB, Shield R. Prevalence of serious mental illness and under 65 population in nursing homes continues to grow. J Am Med Dir Assoc. 2022;23(7):1262–1263 https://doi.org/10.1016/j.jamda.2021.10.020.
Cook A, Averett S. Do hospitals respond to changing incentive structures? Evidence from medicare’s 2007 DRG restructuring. J Health Econ. 2020;73: 102319.
Dafny LS. How do hospitals respond to price changes? Am Econ Rev. 2005;95(5):1525–47.
Davis CS. The SUPPORT for patients and communities act—what will it mean for the opioid-overdose crisis? N Engl J Med. 2019;380(1):3–5.